Stay the course! ...or buy more at this level if you can. There has been no bad news from the company. It is just a matter of time before RNN's drugs get pushed through the pipleline, partnered with, or bought out. The founder and current Chief Scientific Officer, Dr. Chang Ahn, knows what he is doing. He use to work hands on as employee for the FDA and has the experience and connections to get expedited in a timely manner. They are still achieving their MTD levels and they keep getting higher with no serious side effects, which is a good thing. The drugs and platform technology our valuable now and will be a commodity in the future.
News 
Market Data 
Discover 
AI
